Diseases of the central nervous system (CNS) and mental health issues represent a major burden on society, and there is considerable room for improvements of the current therapeutic alternatives. Swedish pharma company Gabather is working to alleviate this burden by developing therapies targeting the GABA\A \receptor, which is involved in a wide range of CNS illnesses, in particular psychiatric disorders like schizophrenia, depression and anxiety. BioStock got in touch with CEO Dr Michael-Robin Witt to learn more about the company and its strategy for bringing new treatments to CNS disease patients.
Read the full interview with Dr Michael-Robin Witt at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital.